Routine use of thiopurines in maintaining remission in pediatric Crohn’s disease

Table 1 Demographics-primary analysis n (%)

	Included (n = 65)	Excluded (n = 117)	P value
Age (yr)	12.98 ± 2.8	13.4 ± 2.9	NS
Gender
Male	39 (60.0)	65 (55.6)	NS
Female	26 (40.0)	52 (44.4)
Disease duration
< 12 mo
> 12 mo	59 (90.7)	100 (85.5)	NS
	6 (9.2)	17 (14.5)
Race
Caucasian	52 (80.0)	102 (87.2)	NS
Disease location
Upper	37 (56.9)	79 (67.5)	NS
Ileal	49 (75.4)	91 (77.9)	NS
Colonic	54 (83.1)	97 (82.9)	NS
Thiopurine
6MP	42 (64.6)	87 (77.0)	NS
AZA	23 (35.4)	26 (23.0)
PGA
Remission	7 (10.8)	5 (4.4)	NS
Mild	22 (33.8)	41 (36.3)
Moderate	31 (47.7)	58 (51.3)
Severe	5 (7.7)	9 (8.0)
Mean initiation dosage
(mg/kg)	0.89 ± 0.31	1.06 ± 0.37	0.002
6TG level	258 ± 147	231 ± 161	NS
(pmole/8 × 108 RBC)	(n = 31)	(n = 55)

NS: No significant.